Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to find the highest dose of the investigational immunotherapy drug REGN7075 that can be given alone and in combination with cemiplimab in people with inoperable or metastatic solid tumors. Patients will either receive REGN7075 alone followed by REGN7075 plus cemiplimab, or only combination treatment with REGN7075 plus cemiplimab. Both drugs are given intravenously (by vein).
The purpose of this study is to find the highest dose of the investigational drug RP-6306 that can be used in advanced solid tumors containing certain genetic changes and which have come back or continued to grow despite prior treatment.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the most effective treatments for prostate cancers that have spread to other organs (metastasized). The benefits of hormone treatments do not last, however. Over time, many prostate cancers continue to grow despite hormonal therapies; these are called "castration-resistant prostate cancers" (CRPC).
Doctors routinely use intensity-modulated radiation therapy (IMRT) after surgery to treat squamous cell carcinoma (cancer) of the tongue. IMRT delivers radiation directly to cancer cells from different angles by changing the radiation beam into multiple smaller beams. By targeting the tumor more precisely, IMRT reduces radiation damage to healthy tissue.
Researchers want to see if AAA617 can slow the growth of advanced prostate cancer. They also want to learn if this treatment can delay the need to start hormonal therapy. Treatment with AAA617 will be compared to observation (no treatment other than standard targeted radiation therapy).
Researchers are seeing how well the drug FORE8394 works in people with advanced solid tumors, including brain tumors. The people in this study include adults and children with cancers that keep growing or came back even with treatment. Their tumors have mutations (changes or variants) in the BRAF gene.
The purpose of this study is to assess the safety and effectiveness of combination therapy with zanubrutinib, obinutuzumab, and venetoclax in patients newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).
Researchers want to see if a single radiation therapy dose can limit the growth of colorectal cancer liver metastases. The people in this study have colorectal cancer that has metastasized (spread) to the liver. The treatment is called high-dose stereotactic body radiation therapy (SBRT).
However, SBRT may not be enough for people with intermediate-risk prostate cancer and unfavorable genetic features. These features may make it more likely that the cancer will come back after radiation therapy. These people may benefit from SBRT with hormonal therapy early in their care.
Researchers want to see if giving NALIRIFOX chemotherapy with high-dose radiation therapy and capecitabine before surgery helps people with pancreatic cancer. The people in this study have pancreatic cancer that involves major blood vessels but has not spread to other organs. The study includes people with pancreatic cancer that may or may not be removable ("borderline resectable" or "locally advanced").
